Abstract
Introduction: Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) belong to the group of keratinocyte carcinomas (KC). Actinic keratosis (AK) is a precursor lesion of cSCC. The incidences of cSCC, BCC, and AK are currently strongly increasing. Different standard therapies exist for these conditions but are not always applicable or successful. Hydrophilic Viscum album extracts have been used in anthroposophic cancer therapy since 1917. Viscum album lipophilic extract (VALE) is prepared by means of supercritical CO2 extraction. This retrospective case series assessed the safety and clinical effects of a topical application of 10% VALE in individual cases of cSCC, BCC, and AK. Methods: For this retrospective case series, a positive vote was obtained from the Ethics Committee of the University of Witten/Herdecke (No. 146/2020). Eligible patients signed a declaration of consent prior to inclusion in the study. The main outcome parameters were the clinical response to treatment with VALE and adverse drug reactions. Risk factors, concomitant therapies and diseases, further diagnostic and therapeutic information were documented where available. Data analysis was performed on the level of patients and of individual lesions. Results: The study population consisted of 55 patients with 74 skin lesions. Individual case analysis accompanied by photographic documentation revealed typical and promising treatment courses. Clinical response rates (complete + partial remissions) for individual lesions were 78% for cSCC, 70% for BCC, and 71% for AK. Complete remission rates for individual lesions were 56% for cSCC, 35% for BCC, and 15% for AK. In cSCC and BCC, shorter times to best clinical response were observed. Adverse drug reactions were reported in 5 patients including erythema and inflammatory reactions of mostly moderate severity that resolved completely. In one case, therapy was temporarily paused, in four cases it was continued without interruption. Discussion/Conclusion: The results of this study suggest that VALE is a safe and tolerable extract under whose application complete and partial remissions of KC could be observed. To improve and assess the efficacy of VALE, prospective investigations are necessary.
Journal Section:
Research Article / Originalarbeit
References
1.
Costa
C
, Scalvenzi
M
, Ayala
F
, Fabbrocini
G
, Monfrecola
G
. How to treat actinic keratosis? An update
. J Dermatol Case Rep
. 2015
;9
(2
):29
–35
. 2.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft
, Deutsche
Krebshilfe
, AWMF). Aktinische Keratose und Plattenepithelkarzinom der Haut
, Langversion
2
.0
, 2022
AWMF-Registernummer
: 032/022OL. Available from:
https://www.leitlinienprogramm-onkologie.de/leitlinien/aktinische-keratose-und-plattenepithelkarzinom-der-haut/(accessed 28.11.2023).
3.
Selg
P
. Mensch und Mistel. Die Begründung der onkologischen Viscum-Behandlung durch Rudolf Steiner und Ita Wegman. Band 1: 1917-1925
. Berlin
: Salumed
; 2016
.4.
Kuonen
R
, Weissenstein
U
, Baumgartner
S
, Urech
K
. Effects of Viscum album lipophilic extract and oleanolic acid on migratory activity of NIH/3T3 fibroblasts
. Eur J Integr Med
. 2012
;4
(1
):125
–6
. .5.
Weissenstein
U
, Toffol
U
, Baumgartner
S
, Urech
K
. Immunomodulatory and anti-apoptotic effects of Viscum album lipophilic extract and oleanolic acid on human peripheral blood lymphocytes and monocytes IN VITRO European
. J Integr Med
. 2012
;4
(1
):124
.6.
Kuonen
R
, Weissenstein
U
, Urech
K
, Kunz
M
, Hostanska
K
, Estko
M
, et al. Effects of lipophilic extract of Viscum album L. And oleanolic acid on migratory activity of NIH/3T3 fibroblasts and on HaCat keratinocytes
. Evid Based Complement Alternat Med
. 2013
;2013
:718105
. 7.
Urech
K
, Scher
JM
, Hostanska
K
, Becker
H
. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L
. J Pharm Pharmacol
. 2005
;57
(1
):101
–9
. 8.
Urech
K
, Hostanska
K
, Scher
J
, Giannattasio
M
, Becker
H
. Antiproliferative activity of lipoid fractions from Viscum album L. on leukemia cells
. Proc 3rd Int Symp Nat Drugs Naples
. 2003
;79-81
:79
–81
.9.
Products
CHM
. Guidelines for good clinical practice E6 (R2)
. In: Products
CHM
, editor. Revision 22002
. European Medicines Agency
.10.
Hoffmann
W
, Latza
U
, Baumeister
SE
, Brunger
M
, Buttmann-Schweiger
N
, Hardt
J
, et al. Guidelines and recommendations for ensuring good epidemiological practice (GEP): a guideline developed by the German society for epidemiology
. Eur J Epidemiol
. 2019
;34
(3
):301
–17
. 11.
Agha
RA
, Borrelli
MR
, Farwana
R
, Koshy
K
, Fowler
AJ
, Orgill
DP
, et al. The PROCESS 2018 statement: updating consensus preferred reporting of CasE series in surgery (PROCESS) guidelines
. Int J Surg
. 2018
;60
:279
–82
. 12.
Freites-Martinez
A
, Santana
N
, Arias-Santiago
S
, Viera
A
. Using the Common Terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies
. Actas Dermosifiliogr
. 2021
;112
(1
):90
–2
. 13.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
. Eur J Cancer
. 2009
;45
(2
):228
–47
. 14.
Abramson
JH
. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists
. Epidemiol Perspect Innov
. 2004
;1
(1
):6
. 15.
Fitzpatrick
TB
. The validity and practicality of sun-reactive skin types I through VI
. Arch Dermatol
. 1988
;124
(6
):869
–71
. 16.
Olsen
EA
, Abernethy
ML
, Kulp-Shorten
C
, Callen
JP
, Glazer
SD
, Huntley
A
, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck
. J Am Acad Dermatol
. 1991
;24
(5 Pt 1
):738
–43
. 17.
Steiner
R
. Geisteswissenschaft und Medizin: 20 Vorträge, gehalten in Dornach vom 21. März bis 09.April 1920 vor Ärzten und Medizinstudenten
. Dornach
: Rudolf Steiner Verlag
; 1985
.18.
19.
Koch
EAT
, Wessely
A
, Steeb
T
, Berking
C
, Heppt
MV
. Safety of topical interventions for the treatment of actinic keratosis
. Expert Opin Drug Saf
. 2021
;20
(7
):801
–14
. 20.
Blauvelt
A
, Kempers
S
, Lain
E
, Schlesinger
T
, Tyring
S
, Forman
S
, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis
. N Engl J Med
. 2021
;384
(6
):512
–20
. 21.
Jansen
MHE
, Kessels
J
, Nelemans
PJ
, Kouloubis
N
, Arits
A
, van Pelt
HPA
, et al. Randomized trial of four treatment approaches for actinic keratosis
. N Engl J Med
. 2019
;380
(10
):935
–46
. 22.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
. Aktinische Keratose und Plattenepithelkarzinom der Haut
. Langversion 1.1, 2020, AWMF-Registernummer: 032/022OL
. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/aktinische-keratose-und-plattenepithelkarzinom-der-haut/ (accessed 28.11.2023).23.
Sinclair
R
, Baker
C
, Spelman
L
, Supranowicz
M
, MacMahon
B
. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies
. Australas J Dermatol
. 2021
;62
(2
):119
–23
. 24.
Gross
K
, Kircik
L
, Kricorian
G
. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction
. Dermatol Surg
. 2007
;33
(4
):433
–40
; discussion 40. 25.
Love
WE
, Bernhard
JD
, Bordeaux
JS
. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review
. Arch Dermatol
. 2009
;145
(12
):1431
–8
. 26.
Nagarajan
P
, Asgari
MM
, Green
AC
, Guhan
SM
, Arron
ST
, Proby
CM
, et al. Keratinocyte carcinomas: current concepts and future research priorities
. Clin Cancer Res
. 2019
;25
(8
):2379
–91
. 27.
Heppt
MV
, Leiter
U
, Steeb
T
, Amaral
T
, Bauer
A
, Becker
JC
, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma: short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators
. J der Deutschen Dermatologischen Gesellschaft
. 2020
;18
(3
):275
–94
. 28.
Koch
E
, Wessely
A
, Steeb
T
, Berking
C
, Heppt
M
. Safety of topical interventions for the treatment of actinic keratosis
. Expert Opin Drug Saf
. 2021
;20
(7
):801
–14
. 29.
Salim
A
, Leman
JA
, McColl
JH
, Chapman
R
, Morton
CA
. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease
. Br J Dermatol
. 2003
;148
(3
):539
–43
. 30.
Morton
C
, Horn
M
, Leman
J
, Tack
B
, Bedane
C
, Tjioe
M
, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial
. Arch Dermatol
. 2006
;142
(6
):729
–35
. 31.
Askew
DA
, Mickan
SM
, Soyer
HP
, Wilkinson
D
. Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials
. Int J Dermatol
. 2009
;48
(5
):453
–63
. 32.
Seger
EW
, Tarantino
IS
, Neill
BC
, Wang
T
. Relative efficacy of nonoperative treatment of keratoacanthomas
. J Cutan Med Surg
. 2020
;24
(1
):41
–6
. 33.
Dohil
MA
. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis
. J Drugs Dermatol
. 2016
;15
(10
):1218
–24
.34.
Stockfleth
E
, Sibbring
GC
, Alarcon
I
. New topical treatment options for actinic keratosis: a systematic review
. Acta Derm Venereol
. 2016
;96
(1
):17
–22
. 35.
Stockfleth
E
, von Kiedrowski
R
, Dominicus
R
, Ryan
J
, Ellery
A
, Falqués
M
, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial
. Dermatol Ther
. 2017
;7
(1
):81
–96
. 36.
Hadley
G
, Derry
S
, Moore
RA
. Imiquimod for actinic keratosis: systematic review and meta-analysis
. J Invest Dermatol
. 2006
;126
(6
):1251
–5
. 37.
Vun
Y
, Siller
G
. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study
. Australas J Dermatol
. 2006
;47
(3
):169
–71
. 38.
Brinkhuizen
T
, Frencken
KJ
, Nelemans
PJ
, Hoff
ML
, Kelleners-Smeets
NW
, Zur Hausen
A
, et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial
. J Am Acad Dermatol
. 2016
;75
(1
):126
–34
. 39.
Siller
G
, Rosen
R
, Freeman
M
, Welburn
P
, Katsamas
J
, Ogbourne
SM
. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial
. Australas J Dermatol
. 2010
;51
(2
):99
–105
. 40.
Ramsay
JR
, Suhrbier
A
, Aylward
JH
, Ogbourne
S
, Cozzi
SJ
, Poulsen
MG
, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers
. Br J Dermatol
. 2011
;164
(3
):633
–6
. 41.
Lee
DW
, Ahn
HH
, Kye
YC
, Seo
SH
. Clinical experience of ingenol mebutate gel for the treatment of Bowen’s disease
. J Dermatol
. 2018
;45
(4
):425
–30
. 42.
Lebwohl
M
, Swanson
N
, Anderson
LL
, Melgaard
A
, Xu
Z
, Berman
B
. Ingenol mebutate gel for actinic keratosis
. N Engl J Med
. 2012
;366
(11
):1010
–9
. 43.
Pflugfelder
A
, Andonov
E
, Weide
B
, Dirschka
T
, Schempp
C
, Stockfleth
E
, et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial
. Br J Dermatol
. 2015
;172
(4
):926
–32
. 44.
Huyke
C
, Reuter
J
, Rodig
M
, Kersten
A
, Laszczyk
M
, Scheffler
A
, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study
. J der Deutschen Dermatologischen Gesellschaft
. 2009
;7
(2
):128
–33
. 45.
Huyke
C
, Laszczyk
M
, Scheffler
A
, Ernst
R
, Schempp
CM
. Treatment of actinic keratoses with birch bark extract: a pilot study
. J Deutsche Derma Gesell
. 2006
;4
(2
):132
–6
. 46.
Kempers
S
, DuBois
J
, Forman
S
, Poon
A
, Cutler
E
, Wang
H
, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results
. J Drugs Dermatol
. 2020
;19
(11
):1093
–100
. 47.
Cornell
RC
, Greenway
HT
, Tucker
S
, Edwards
L
, Ashworth
S
, Vance
JC
, et al. Intralesional interferon therapy for basal cell carcinoma
. J Am Acad Dermatol
. 1990
;23
(4 Pt 1
):694
–700
. 48.
Bath-Hextall
FJ
, Matin
RN
, Wilkinson
D
, Leonardi-Bee
J
. Interventions for cutaneous Bowen’s disease
. Cochrane Database Syst Rev
. 2013
;2013
(6
):CD007281
. 49.
Stockfleth
E
, Kerl
H
, Zwingers
T
, Willers
C
. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results
. Br J Dermatol
. 2011
;165
(5
):1101
–8
. 50.
Karsai
S
, Friedl
H
, Buhck
H
, Junger
M
, Podda
M
. The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial
. Br J Dermatol
. 2015
;172
(3
):677
–83
. 51.
Werner
RN
, Sammain
A
, Erdmann
R
, Hartmann
V
, Stockfleth
E
, Nast
A
. The natural history of actinic keratosis: a systematic review
. Br J Dermatol
. 2013
;169
(3
):502
–18
. 52.
Navarrete-Dechent
C
, Marghoob
AA
, Marchetti
MA
. Contemporary management of actinic keratosis
. J Dermatolog Treat
. 2021
;32
(5
):572
–4
. 53.
Curson
C
, Weedon
D
. Spontaneous regression in basal cell carcinomas
. J Cutan Pathol
. 1979
;6
(5
):432
–7
. 54.
Kwiek
B
, Schwartz
RA
. Keratoacanthoma (KA): an update and review
. J Am Acad Dermatol
. 2016
;74
(6
):1220
–33
. 55.
Sengupta
S
, Arocho
J
, Christopher Windham
T
. Spontaneous regression of a histologically proven cutaneous squamous cell carcinoma
. J Cancer Ther
. 2013
;04
(02
):546
–8
. 56.
Kunz
C
, Heiligtag
HR
, Hintze
A
, Urech
K
. Treatment of basal cell carcinoma with Viscum album lipophilic extract: a case series study
. Phytomedicine
. 2011
;18
(8
):25
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
